Videos

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Tara Seery, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Charles Fuchs, MD: Strategies to Increase RAS Testing

April 26th 2016

Charles Fuchs, MD: Impeding RAS Mutation Testing

April 26th 2016

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Charles Fuchs, MD: Mutations in Colorectal Cancer

April 26th 2016

Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

April 26th 2016

Charles Fuchs, MD: Treatment Toxicities and Quality of Life

April 26th 2016

Charles Fuchs, MD: Chemotherapy Side-Effects

April 26th 2016

Charles Fuchs, MD: Bevacizumab Side-Effects

April 26th 2016

Charles Fuchs, MD: Bevacizumab Plus Chemotherapy

April 26th 2016

Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

April 26th 2016

Tanios Bekaii-Saab, MD: Treatment Toxicities and Quality of Life

April 26th 2016

Videos

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

Tara Seery, MD: Fourth-Line Therapy in mCRC

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

Charles Fuchs, MD: Strategies to Increase RAS Testing

Charles Fuchs, MD: Impeding RAS Mutation Testing

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Charles Fuchs, MD: Clinical Importance of RAS Mutations

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1

Charles Fuchs, MD: Mutations in Colorectal Cancer

Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

Charles Fuchs, MD: Treatment Toxicities and Quality of Life

Charles Fuchs, MD: Chemotherapy Side-Effects

Charles Fuchs, MD: Bevacizumab Side-Effects

Charles Fuchs, MD: Bevacizumab Plus Chemotherapy

Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

Tanios Bekaii-Saab, MD: Treatment Toxicities and Quality of Life

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer

Dr Mardones on Giredestrant’s Numerical PFS Edge in Advanced Breast Cancer

Gedatolisib Combinations Double PFS in PIK3CA-Mutant Breast Cancer

Revumenib Maintenance After Allogeneic SCT Shows Feasibility in AML

FDA OKs Oral Nilotinib Tablets for Ph+ CML With Acid-Reducer Flexibility